Fiona Clegg

Medicine & Life Sciences

1. Infliximab 100%
2. Bile Acids and Salts 88%
3. Colitis 87%
4. Liver Neoplasms 85%
5. Microbiota 84%
6. Gastrointestinal Microbiome 84%
7. Documentation 80%
8. 23-seleno-25-homotaurocholic acid 73%
9. Inflammatory Bowel Diseases 70%
10. Colorectal Neoplasms 68%
11. Consent Forms 57%
12. Checklist 34%
13. Paracentesis 27%
14. Colectomy 23%
15. Therapeutics 23%
16. Liver Cirrhosis 21%
17. Ulcerative Colitis 21%
18. Biological Products 21%
19. Hepatocellular Carcinoma 20%
20. Crohn Disease 20%
21. Liver Diseases 20%
22. Neoplasms 16%
23. Steroids 15%
24. Palliative Care 15%
25. Survival 14%
26. Healthcare-Associated Pneumonia 14%
27. Anastomotic Leak 12%
28. Blood Platelets 11%
29. National Institutes of Health (U.S.) 11%
30. Wound Infection 11%
31. Response Evaluation Criteria in Solid Tumors 10%
32. Transplants 10%
33. Cytomegalovirus 10%
34. Pulmonary Embolism 10%
35. Cyclosporine 10%
36. Mortality 9%
37. Patient Selection 9%
38. Non-alcoholic Fatty Liver Disease 9%
39. Consultants 9%
40. Liver 8%
41. Practice Management 8%
42. Ticks 8%
43. International Normalized Ratio 8%
44. Gastroenterology 8%
45. Hepacivirus 7%
46. Radiologists 7%
47. Doxorubicin 7%
48. Liver Transplantation 7%
49. Tumor Necrosis Factor-alpha 7%
50. Colesevelam Hydrochloride 7%